• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Friday, November 20, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Glioma Multi-Omics Study Identifies Candidate Regulatory Circuit and Prognostic Risk Model

by
November 19, 2026
in Health
Reading Time: 5 mins read
0
Glioma Multi-Omics Study Identifies Candidate Regulatory Circuit and Prognostic Risk Model

Glioma Multi-Omics Study Identifies Candidate Regulatory Circuit and Prognostic Risk Model

Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

A multi-omics investigation integrating public transcriptomic profiles with cellular perturbation assays has characterized a candidate regulatory relationship involving the long non-coding RNA GNG12-AS1, the microRNA miR-138-5p, and 3-phosphoinositide-dependent protein kinase 1, alongside an analytically separate twelve-feature prognostic risk model for glioma. Gliomas represent the most frequent primary malignant neoplasms of the central nervous system and display substantial molecular heterogeneity, histological diversity, and variable clinical behavior. Although contemporary neuro-oncology management incorporates integrated diagnostic markers such as isocitrate dehydrogenase mutation status, 1p/19q co-deletion, and O-6-methylguanine-DNA methyltransferase promoter methylation, clinical outcomes remain heterogeneous even across matching molecular groups. Maximal surgical resection combined with radiotherapy and temozolomide chemotherapy constitutes the established therapeutic backbone, yet recurrence and therapeutic resistance remain widespread clinical challenges.

To address the challenge of biological complexity, researchers led by Lingtong You, Jinning Zhang, and colleagues evaluated whether candidate non-coding regulatory elements correlate with key signaling kinases and patient survival. The team investigated the competing endogenous RNA hypothesis, which suggests that long non-coding RNAs and messenger RNAs can cross-talk by competitively binding shared microRNA response elements. Because predicted RNA communication networks can be context-dependent, the investigators sought to distinguish computationally nominated candidate axes from confirmed molecular mechanisms. The study maintained a strict analytical separation between the proposed GNG12-AS1/miR-138-5p/PDPK1 candidate interaction and an independently derived prognostic gene expression signature, explicitly avoiding claims of a validated causal regulatory circuit in the absence of direct RNA-binding and rescue assays.

The analytical design incorporated large-scale computational cohorts alongside focused cell-line experiments. Primary transcriptomic modeling and miRNA evaluations were conducted using Chinese Glioma Genome Atlas datasets, specifically the CGGA_mRNAseq_693 cohort comprising 693 patients, the CGGA_mRNAseq_325 validation cohort of 325 patients, and the CGGA_microRNA_198 dataset. Supplementary contextual analysis utilized The Cancer Genome Atlas lower-grade glioma and glioblastoma resource, encompassing approximately 809 candidate-molecule RNA sequencing profiles, 784 miR-138-5p isoform records, and 661 primary tumor records linked to clinical survival outcomes. Single-cell transcriptomic resolution was established using the CGGA_scRNAseq_6148 dataset, which yielded 4,738 high-quality single cells across 75 clinical records following standard filtering, quality control, dimensional reduction, and unsupervised clustering.

Statistical evaluations across the bulk tumor resources clarified the correlation structure among the three candidate molecules. Pairwise Spearman rank correlation analyses adjusted by the Benjamini-Hochberg false discovery rate control in TCGA datasets revealed a weak positive association between GNG12-AS1 and miR-138-5p, with a correlation coefficient rho of 0.084 and an FDR of 0.042. A significant inverse association emerged between miR-138-5p and PDPK1, yielding a correlation coefficient rho of negative 0.217 and an FDR below 0.001. Conversely, the direct association between GNG12-AS1 and PDPK1 demonstrated a weak positive coefficient rho of 0.064 with an FDR of 0.086, failing to surpass the formal significance threshold. Because these pairwise patterns showed positive GNG12-AS1 to miR-138-5p alignment alongside an inverse microRNA to target kinase trend, the authoring team emphasized that the bulk correlation profiles alone do not constitute evidence for a canonical competing endogenous RNA axis.

Single-cell dissection provided cellular mapping for the candidate genes across tumor, immune, and stromal compartments. Single-cell RNA sequencing showed that PDPK1 was detected in 34.85 percent of profiled cells, demonstrating an average log-normalized expression level of 0.194 in glioma-associated cellular compartments, while clearly separating from the distinct metabolic kinase gene PDK1. In contrast, GNG12-AS1 displayed low detectability in single-cell droplet libraries, registering in only 2.01 percent of cells with an average expression of 0.010, which reflects recognized technical constraints in capturing low-abundance nuclear non-coding transcripts. Because mature microRNAs are not directly captured by standard single-cell sequencing protocols, miR-138-5p biological context was inferred through downstream target-gene signature scores rather than direct RNA quantification.

Functional enrichment and pathway activity scoring linked PDPK1 expression to fundamental oncogenic cascades. Gene Ontology and Kyoto Encyclopedia of Genes and Genomes over-representation analyses connected candidate-associated gene sets to cell-cycle progression, DNA replication, extracellular-matrix organization, cellular migration, angiogenesis, and inflammatory pathways. Gene set enrichment analysis in the primary CGGA cohort showed positive enrichment of the PI3K/AKT/mTOR signaling cascade in PDPK1-high tumors, exhibiting a normalized enrichment score of 1.59 and an FDR below 0.001. Similarly, a composite two-gene expression-context score combining normalized z-scores of PDPK1 and GNG12-AS1 displayed significant enrichment of mTOR signaling (NES 1.70, FDR less than 0.001) and elevated pathway activity relative to low-score tumors (delta 0.69, FDR less than 0.001). Curated ligand-receptor communication analyses further revealed elevated interactions between malignant cells and tumor-associated macrophages, highlighting SPP1-CD44 and SPP1-ITGAV communication pathways.

Experimental perturbation assays in cultured U251 human glioma cells supplied functional testing of the candidate pathway nodes. Cells were transfected with small interfering RNAs targeting GNG12-AS1 or PDPK1, or treated with a miR-138-5p synthetic mimic alongside negative control oligonucleotides. Reverse transcription-quantitative PCR confirmed specific knockdown and overexpression efficiency. Depletion of GNG12-AS1 significantly reduced PDPK1 transcript levels, whereas transfection of the miR-138-5p mimic similarly suppressed PDPK1 mRNA. Quantitative intracellular flow cytometry documented corresponding reductions in normalized geometric mean fluorescence intensity for PDPK1 protein and AKT phosphorylated at threonine 308, while total AKT protein levels remained stable across all conditions. Annexin V and propidium iodide flow cytometric assays demonstrated an increase in apoptotic cell fractions following GNG12-AS1 silencing, miR-138-5p mimic introduction, or direct PDPK1 knockdown across three independent biological replicates.

Separately from the molecular assays, the researchers constructed a twelve-feature transcriptomic prognostic model from 13,011 shared features using a univariable Cox screening and a ten-fold cross-validated LASSO Cox regression workflow. At the optimal lambda parameter of 0.1821974, twenty features retained non-zero coefficients, and the top twelve candidates were integrated into a final locked multivariable Cox model comprising KIF2C, PLAT, IGF2BP3, KCNJ11, RP11-189B4.6, HOXA7, TPTE2P1, RGS16, IGFBP5, CXXC11, TROAP, and RP11-18I14.10. None of the three candidate network molecules were forced into or selected by the prognostic model pipeline. The locked twelve-feature model achieved a concordance index of 0.772 in the CGGA693 training cohort and 0.744 in the CGGA325 validation cohort when applied using fixed coefficients and a locked cutoff of negative 0.1061954 without refitting.

The clinical relevance and incremental discrimination of the prognostic score were evaluated across clinicopathological subgroups. Risk scores were significantly elevated in higher World Health Organization glioma grades (n = 966, Kruskal-Wallis P = 2.32 × 10^-76) and in IDH-wildtype tumors (n = 921, Cliff’s delta = 0.669, 95% CI 0.615–0.719). In a pooled complete-case analysis of 715 patients with 480 mortality events, incorporating the standardized risk score into a multivariable clinical model containing age, grade, IDH status, 1p/19q codeletion, MGMT methylation, and cohort indicator yielded an independent association with overall survival (hazard ratio per 1-SD increase = 2.085, 95% CI 1.802–2.413, P = 6.31 × 10^-23) and increased the overall C-index by 0.030 (bootstrap 95% CI 0.016–0.045). Proportional-hazards diagnostics revealed non-proportionality for grade and IDH status, but stratified sensitivity models confirmed the stability of the risk score hazard ratio.

Pharmacogenomic screening applied ridge regression models trained on Genomics of Drug Sensitivity in Cancer 2 data to predict drug response profiles in bulk cohorts. Across both CGGA cohorts, forty-two therapeutic compounds exhibited concordant lower predicted log-response values in high-risk tumors, indicative of lower IC50-like phenotype predictions. AZD3759 was identified as the primary computational candidate, demonstrating a Cliff’s delta of negative 0.384 in the training cohort and negative 0.554 in the validation cohort, accompanied by a held-out cell-line correlation rho of 0.368 and documented blood-brain barrier penetration in published non-small-cell lung cancer literature. Nevertheless, the study authors explicitly emphasized that these computational drug predictions reflect exploratory prioritization candidates rather than measured patient responses or clinical treatment recommendations, and direct RNA-binding and causal-rescue validations remain essential before defining therapeutic strategies.

Subject of Research: Glioma transcriptomic profiling, candidate RNA regulatory mechanisms, and prognostic modeling

Article Title: Multi-omics investigation of the GNG12-AS1/miR-138-5p/PDPK1 candidate regulatory relationship and transcriptome-derived prognostic modeling in glioma

Article References: You, L., Huang, J., Yang, H., Wei, J., Yu, Z., & Zhang, J. (2026). Multi-omics investigation of the GNG12-AS1/miR-138-5p/PDPK1 candidate regulatory relationship and transcriptome-derived prognostic modeling in glioma. Frontiers in Neurology, 17, Article 1939176. https://doi.org/10.3389/fneur.2026.1939176

Image Credits: AI Generated

DOI: 10.3389/fneur.2026.1939176

Keywords: glioma, GNG12-AS1, miR-138-5p, PDPK1, multi-omics, prognostic model, transcriptomics, TCGA, CGGA, single-cell RNA sequencing, U251 cell line, flow cytometry, RT-qPCR, AZD3759, PI3K/AKT signaling, tumor microenvironment, LASSO regression

News Source: Ophelia Keating. (November 19, 2026). Glioma Multi-Omics Study Identifies Candidate Regulatory Circuit and Prognostic Risk Model. Scienmag.

Tags: AZD3759CGGAflow cytometrygliomaGNG12-AS1LASSO regressionmiR-138-5pmulti-omicsPDPK1PI3K/Akt signalingprognostic modelRT-qPCRsingle-cell RNA sequencingTCGATranscriptomicstumor microenvironmentU251 cell line
Share12Tweet7Share2ShareShareShare1

Related Posts

Higher Pharmacist Staffing Strongly Associates With Hospital Ward Service Adoption in Japan

Higher Pharmacist Staffing Strongly Associates With Hospital Ward Service Adoption in Japan

November 20, 2026
Healthcare Spending Drivers in Tanzania Vary Substantially Between Rural and Urban Households

Healthcare Spending Drivers in Tanzania Vary Substantially Between Rural and Urban Households

November 20, 2026

Third-Generation EGFR Inhibitors Show Inconclusive Efficacy in Uncommon Lung Cancer Mutations

November 20, 2026

Review Finds European Adult Thiamin Deficiency Ranges Widely Up to 41 Percent

November 20, 2026

POPULAR NEWS

  • Gene Knockouts and Buffer Systems Boost Bacillus subtilis Spore Display Yields

    Gene Knockouts and Buffer Systems Boost Bacillus subtilis Spore Display Yields

    29 shares
    Share 12 Tweet 7
  • Narrative Review Integrates Imaging, Biomechanics, and Movement in Lumbar Spondylolysis

    29 shares
    Share 12 Tweet 7
  • Bifrontal Brain Stimulation Improves Working Memory in Schizophrenia Without Sex Differences

    29 shares
    Share 12 Tweet 7
  • Robotic and Conventional Knee Replacements Show Comparable One-Year Joint Infection Rates

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Higher Pharmacist Staffing Strongly Associates With Hospital Ward Service Adoption in Japan

Healthcare Spending Drivers in Tanzania Vary Substantially Between Rural and Urban Households

Third-Generation EGFR Inhibitors Show Inconclusive Efficacy in Uncommon Lung Cancer Mutations

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 89 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.